Open AccessCost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population
Author(s) -
Elizabeth R. Stevens,
Kimberly A. Nucifora,
Holly Hagan,
Ashly E. Jordan,
Jennifer Uyei,
Bilal Khan,
Kirk Dombrowski,
Don Des Jarlais,
R. Scott Braithwaite
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz726
Subject(s) - medicine , cost effectiveness , population , quality adjusted life year , economic evaluation , cost effectiveness analysis , hepatitis c , cost–benefit analysis , psychological intervention , syringe , environmental health , emergency medicine , psychiatry , risk analysis (engineering) , ecology , pathology , biology
There are too many plausible permutations and scale-up scenarios of combination hepatitis C virus (HCV) interventions for exhaustive testing in experimental trials. Therefore, we used a computer simulation to project the health and economic impacts of alternative combination intervention scenarios for people who inject drugs (PWID), focusing on direct antiviral agents (DAA) and medication-assisted treatment combined with syringe access programs (MAT+).